KPTI (Karyopharm Therapeutics) PB Ratio: (As of Jul. 02, 2026)


KPTI Karyopharm Therapeutics Inc KPTI
52 GF Score
Price $9.60
GF Value $6.37
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-02), Karyopharm Therapeutics's share price is $9.60. Karyopharm Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $-11.78. Hence, Karyopharm Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Karyopharm Therapeutics's PB Ratio or its related term are showing as below:

During the past 13 years, Karyopharm Therapeutics's highest PB Ratio was 32.86. The lowest was 1.39. And the median was 4.99.

KPTI's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.95
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was -93.50% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Karyopharm Therapeutics was -9.60% per year. The lowest was -93.50% per year. And the median was -25.50% per year.

Back to Basics: PB Ratio


Karyopharm Therapeutics  (NAS:KPTI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Karyopharm Therapeutics PB Ratio Related Terms


Karyopharm Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics PB Ratio Chart

Karyopharm Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Karyopharm Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KPTI vs CHRS, TARA, CNTN: PB Ratio Comparison

For the Biotechnology subindustry, Karyopharm Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's PB Ratio falls into.


KPTI
52GF Score
Karyopharm Therapeutics Inc KPTI
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Karyopharm Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Karyopharm Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=9.60/-11.783
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $9.60 is trading 50.7% above its estimated GF Value™ of $6.37. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

  • PB Ratio:
  • GF Value™: $6.37 vs. price of $9.60 (50.7% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score

Get the complete analysis for KPTI

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.60
Price
$6.37
GF Value